Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30799506 | 0.98 | PDPK1 (0.44) | PDPK1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29858433 | 0.80 | PDPK1 (0.52) | PDPK1HTR2A | |
| SCHEMBL7500388 | 0.80 | PDPK1 (0.52) | PDPK1HTR2A | |
| SCHEMBL22997177 | 0.80 | PDPK1 (0.52) | PDPK1HTR2A | |
| SCHEMBL130896 | 0.80 | PDPK1 (0.52) | PDPK1HTR2A | |
| SCHEMBL31136765 | 0.80 | POLB (0.40) | PDPK1SLC6A2SLC6A3HTR2A | |
| SCHEMBL24915634 | 0.79 | LTB4R (0.45) | CYP2D6SLC6A2SLC6A4HTR2ALTB4R | |
| SCHEMBL5019356 | 0.79 | HTR2A (0.48) | CYP2D6SLC6A2SLC6A4SLC6A3HTR2A | |
| SCHEMBL3829666 | 0.76 | P2RX7 (0.45) | HTR2ALTB4RLTB4R2 | |
| SCHEMBL14682162 | 0.76 | CYP19A1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070134-A | Use of PRMT5 inhibitors in the treatment of tumors or cancers | 上海湃隆生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025077857-A1 | USE OF PRMT5 INHIBITOR IN TREATMENT OF TUMORS OR CANCERS | 上海湃隆生物科技有限公司 | 2025-04-17 | — | — | WO | disclosed |
| WO-2024067433-A1 | NOVEL PRMT5 INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2024-04-04 | — | — | WO | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | US | disclosed |
| EP-2649069-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-1720836-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8580780-B2 | 6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist | ELI LILLY AND COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2479168-A1 | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists | ELI LILLY AND COMPANY (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | ELI LILLY AND COMPANY (US) | 2012-02-02 | — | — | US | disclosed |
| US-8022062-B2 | 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ARRAY BIOPHARMA, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099155-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | HTR2C, HTR5A, HTR4 | PDPK1 3535/4885CYP2D6 567/4885SLC6A2 259/4885 |
| US-20220331321-A1 | ANTIMALARIAL AGENTS | CTSL, SERPINA3, SERPINB1 | PDPK1 1974/4885CYP2D6 1520/4885SLC6A2 3513/4885 |
| US-20120028961-A1 | 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist | HTR2C, HTR4, HTR1A | PDPK1 2693/4885CYP2D6 264/4885SLC6A2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.